Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations

Open Access

Review articles synthesize the best available evidence on a topic relevant to the pathogens community.

Lily E. Cohen ,

* E-mail: lily.cohen@icahn.mssm.edu

Affiliation Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

https://orcid.org/0000-0002-2207-8330

⨯
David J. Spiro,

Affiliation Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Cecile Viboud

Affiliation Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America
⨯

Reader Comments (3)

SARS CoV 2
Is the Subject Area "SARS CoV 2" applicable to this article?

Thanks for your feedback.
Respiratory infections
Is the Subject Area "Respiratory infections" applicable to this article?

Thanks for your feedback.
COVID 19
Is the Subject Area "COVID 19" applicable to this article?

Thanks for your feedback.
Pandemics
Is the Subject Area "Pandemics" applicable to this article?

Thanks for your feedback.
Influenza
Is the Subject Area "Influenza" applicable to this article?

Thanks for your feedback.
Viral vaccines
Is the Subject Area "Viral vaccines" applicable to this article?

Thanks for your feedback.
Viral evolution
Is the Subject Area "Viral evolution" applicable to this article?

Thanks for your feedback.
Evolutionary immunology
Is the Subject Area "Evolutionary immunology" applicable to this article?

Thanks for your feedback.